Informed Consent for Non-English **Speaking Research Participants** and the Role of the CRN

Erin Ferraro, BSN, RN, OCN©, Nurse Educator Deborah Grady, MS, BSN, CCRC, Quality Management Coordinator Office of Education and Compliance Center for Cancer Research

Sentember 2024



1

Objectives

- Explain OHSRP policy regarding consenting non-English speaking research participants as it relates to the CRN
- Review the process and documentation for translated ("long form") informed consent documents.
- Review the process and documentation for "short form" informed consent documents.
- Describe how translated consents are provided and when reconsenting may be needed.

2

What is Informed Consent? (IC)

- Having capacity to agree for one's self to participate in a given situation once risks and benefits are understood
- Ongoing process of communication and mutual understanding between the participant and investigator
- Research participant's initial agreement is evidenced by signing an informed consent document (ICD)

Documentation of IC Process -Research Team

- Specific statement in CRIS addressing the informed consent process
- Required per HRPP Policy 301
- CRIS note must include a statement that:
- A discussion occurred
- All questions were reviewed and answered to the participant's satisfaction
- A copy of the signed ICD was given to the participant
- CRIS has an IC process template progress note "Documentation of Research Consent Note"

Role of Verifying ICD - CRN

Some examples from Procedures and Standards of Practice on the Nursing Intranet...

CCND SOP Chemo/Bio

- Venify presence of a signed informed consent form or an assent form for patients under the age of 18.

 i. "Protocol consent" if patient being treated on protocol.

 ii. "Consent to Chemotherapy Biotherapy if being treated on a standard of care the chemotherapy Biotherapy chemotherapy Biotherapy chemotherapy Biotherapy chemotherapy Biotherapy chemotherapy Biotherapy and Biotherapy Chemotherapy Biotherapy Biotherapy Chemotherapy Biotherapy Biotherap


CCND SOP Medication Admin


Prior to the administration of any medication, a nurse assesses and validates the following: A. Informed consent, if applicable.

5


IC for non-English Speaking **Participants**

- OHSRP policy for enrolling non-English speaking participants (Effective March 2024)
- If enrollment of non-English speaking individuals is anticipated, the consent must be translated into the anticipated languages ("long form").
- Short form use acceptable in certain scenarios





10



Signatures on ICD: Long Form **Process**

- Full ICD ("long form") is translated in participant's/ LAR's preferred healthcare language
- Interpreter used to facilitate discussion
- No signatures on the English version
- Signatures on the translated long form:
- Participant/LAR
- Investigator (*even if they do not speak the language, because they have the full English consent to refer to)

11

Objectives

9

- Explain OHSRP policy regarding consenting non-English speaking research participants as it relates to the CRN
- Review the process and documentation for translated ("long form") informed consent documents.
- Review the process and documentation for "short
- Describe how translated consents are provided and when reconsenting may be needed.

form" informed consent documents.

12

Objectives

- Explain OHSRP policy regarding consenting non-English speaking research participants as it relates to the CRN
- Review the process and documentation for translated ("long form") informed consent documents.
- Review the process and documentation for "short form" informed consent documents.
- Describe how translated consents are provided and when reconsenting may be needed.

So When Can Teams Use a Short Form Consent?

- Federal regulations allow use of short form in participant's preferred healthcare language
 - Witness to the consent process is required
 - Short form states that required elements of IC document have been presented orally
- When research teams use the short form consent:
- They must notify the NIH IRB and justify their use of the short form
- They must promptly translate the consent into the participant's language and provide that consent to them once IRB approved (greater than minimal risk studies)

NIH) NATIONAL CANCER INSTITU

13

Signatures on ICD: "Short Form" Process

- "Short form," IRB approved
- Signed by participant
- Signed by witness
- English version, IRB approved
- Signed by investigator
- Signed by witness
- Participant is provided signed copies of both the short and long form consent

16

When is a Witness Required for

- A witness is only required for the short form consent process
- Witness role is to attest, by signature, the validity of the short form consent process and the participant's agreement to participate in the research
- Must be present for the entire oral presentation
- Ideally speaks both languages
- If a CC interpreter facilitates the short form consent process, they are required to serve as the witness

14

Objectives

- Explain OHSRP policy regarding consenting non-English speaking research participants as it relates to the CRN
- Review the process and documentation for translated ("long form") informed consent documents.
- Review the process and documentation for "short form" informed consent documents.
- Describe how translated consents are provided and when reconsenting may be needed.

NIH) NATIONAL CANCE

17

Short Form Consent Process

Participant
uses the IRB approved
Short Form in their
preferred healthcare
language

Oral Translation

Interpreter uses both the IRB
approved English ICD

Interpreter uses both the IRB
approved English ICD and the
IRB approved Short Form
Consent in the participant's
preferred healthcare language.
Witness is present for the
entire process.

ICD = Informed Consent Document

How does the research team provide a translated consent to a participant?

- If a participant already signed the short form consent, they do not need to be reconsented.
- The participant needs to be given a copy of the translated consent (re-signing not needed) by the research team.

NH) NATIONAL CANCER INSTITU

15

What do CRNs need to know about reconsenting?

- When a consent document is revised, the IRB may determine that some, or all, participants need to be reconsented to the new version.
 - Change in study design (e.g. new protocol test/procedure/visit)
 - New or added risk to participation
- The research teams will oversee and document all reconsents per IRB and OHSRP policies.

NIH NATIONAL CANCER INSTITU

19

....ICD Key Points

- If there is a long form translated ICD, a short form is NOT required
- Documentation of consent notes should explain the consent process
- If you have any questions about the consent process or documentation, please contact the research team

22

Pause and Call the Research Team When...

- There is no participant signature anywhere on a consent (short form or long form)
- There is no investigator signature anywhere on a consent (short form or long form)
- No witness signature anywhere on a consent (short form or long form) if it is a short form consent process



9/4/202

Resources

- OHSRP Consent FAQs
- OHSRP Policy 301 Guidance Enrolling Non-English Speaking participants (6/27/24)
- MAS Policy 23-2: Language Access in Clinical Center
- An Overview of IRB Expectations When Non-English Speaking Persons Enroll in Research: The Importance of Ensuring Comprehension (2/1/24)

NIH) NATIONAL CANCER INSTITUT

23

20

ICD Key Points...

- You will continue to see more long form translated ICDs going forward
- Investigators can sign the long form translated ICD because they have the English version to refer to
- Participants should never sign or initial any part of an English ICD if they don't speak English

NH) NATIONAL CANCER INSTITUTE

QUESTIONS?

nciccroec@mail.nih.gov

NATIONAL CANCER INSTITUTE

www.cancer.gov